Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | Effi-DEM |
Trade Name | |
Synonyms | OSE-172|BI 765063|BI-765063|OSE 172|BI765063 |
Drug Descriptions |
Effi-DEM (OSE-172) is a monoclonal antibody to the SIRPa receptor that blocks the CD47-SIRPa interaction to promote macrophage phagocytosis of tumor cells and may stimulate cytotoxic T-cells (PMID: 29873856). |
DrugClasses | Immune Checkpoint Inhibitor 149 |
CAS Registry Number | NA |
NCIT ID | C179278 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
BI 836880 + Effi-DEM + Ezabenlimab | BI 836880 Effi-DEM Ezabenlimab | 0 | 1 |
Cetuximab + Effi-DEM + Ezabenlimab | Cetuximab Effi-DEM Ezabenlimab | 0 | 1 |
Effi-DEM | Effi-DEM | 0 | 1 |
Effi-DEM + Ezabenlimab | Effi-DEM Ezabenlimab | 0 | 4 |
Effi-DEM + Pembrolizumab | Effi-DEM Pembrolizumab | 0 | 1 |